Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
SAN DIEGO, April 20, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will present at the 5th Annual Cell & Gene Therapy Investor Day in Boston on Thursday, April 27, 2017 at 9:25 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
